Welcome message

Early Bird Discount available(50%) until this weekend

Welcome to HEMATOLOGY 2025! We are excited to invite you to join us in Madrid, Spain, on February 24-25, 2025, for an in-depth exploration of the latest advancements in Hematology research. This conference will be an excellent platform for experts, researchers, and professionals to share innovative insights, foster collaboration, and drive progress in understanding and treating hematological conditions. Prepare to engage in stimulating discussions, connect with leading figures in the field, and contribute to shaping the future of Hematology. We look forward to a vibrant exchange of ideas and knowledge at this year’s event!

About Conference

Hematology 2025 gives a creative research area in motivating young ones in developing research fields and provides cutting edge technology for massive innovations. Hematology 2025 covers an in-depths area of science at micro and macro level thus helping to learn about synthesis, characterization, properties and numerous other benefits of Hematology. Meet notable personalities all under one common platform for sharing ideas by exclusive scientists, passionate researchers, and prestigious delegates across the globe.

We are looking further to current meeting success by bringing revolution in the field of Hematology through sharing your concepts, views, and experiences of research work under one roof for a more robust world. We are a globally acknowledged and trusted organization to provide unique scientific and business services through our Journals and we are expanding the functionality of our International conferences.

Conference Brochure

To access the conference brochure, please complete the form with the required details and click on "Download Brochure". The HEMATOLOGY 2025 brochure will then be available for download.

Abstract Submission

To submit your abstract, please fill out the necessary details in the form and click on "Abstract Submission". We will review your submission and get back to you within 24 hours.

Sessions and Tracks

1. Hematology

Hematology is a branch of clinical medicine focused on the diagnosis and treatment of blood disorders and blood cancers. Hematologists and hematopathologists work collaboratively to diagnose conditions and provide the most appropriate treatments when necessary. Diseases treated within the field of Hematology include:

Acute Leukemia, Chronic Leukemia,Plasma Cell disorders,Lymphoma – Hodgkin / Non Hodgkin, Myeloproliferative Neoplasms, Thalassemia and other, haemoglobinopathies, All types of coagulation and thrombotic disorders, Hemoglobin and platelet disorders

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

2. CellTherapy  

Cell Therapy  involves transferring cells into a patient to improve or cure a disease. Initially, blood transfusions were the first routine cell therapy practiced. Over time, bone marrow transplantation became a well-established treatment for various blood disorders, including anemia, leukemia, lymphoma, and rare immunodeficiency diseases. Alternative medical practitioners also perform cell therapy under names like xenotransplant therapy, glandular therapy, and fresh cell therapy. Proponents claim that cell therapy has successfully repaired spinal cord injuries, strengthened weakened immune systems, treated autoimmune diseases like AIDS, and helped patients with neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

3.Stem Cell Research

Advances in hematopoietic stem cell immunology and histocompatibility have an impact on HSC transplantation breakthroughs. Immunotherapy is an important part of the HSC transplant process. In a number of ways, HSC transplantation is connected to cancer immunotherapy. Hematologists who investigate HSCs have become pioneers in the field of induced pluripotent stem cells, which is still in its infancy (iPS). Using the iPS cell fields reprogramming principles, T cells are now being reprogrammed to generate memory stem cells. Hematology, cancer, stem cell biology, and immunology have all been merged to change the definition of a hematologist.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

4. New Drug Development in Hematology

New drug development in hematology focuses on creating innovative treatments for blood disorders such as anemia, leukemia, and lymphoma. Researchers are exploring targeted therapies that address specific genetic mutations and molecular pathways involved in these diseases. Advances in immunotherapy, such as CAR-T cell therapy, have shown promising results in treating certain types of blood cancers. The development process involves rigorous clinical trials to ensure the safety and efficacy of these new drugs. Continued progress in this field aims to improve patient outcomes and provide more effective treatment options for hematologic conditions.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

5. Disorders of Vascular Bleeding

Disorders of vascular bleeding are conditions that cause abnormal bleeding due to issues with blood vessels. These disorders can be genetic, such as hereditary hemorrhagic telangiectasia (HHT) and Ehlers-Danlos syndrome, leading to fragile or malformed blood vessels that bleed easily. Acquired conditions like vitamin C deficiency can also weaken blood vessel walls, resulting in increased susceptibility to bruising and bleeding. Managing these disorders typically requires a combination of medical treatments, lifestyle changes, and sometimes surgical interventions to prevent and control bleeding episodes.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

6. COVID-19 and Hematology

COVID-19 gives as complex medical manifestations, from flu-like signs and symptoms to a couple of organ failure and death. According to the prognosis and remedy protocol for novel coronavirus pneumonia posted through the National Health Commission of China, there are 4 severity tiers of COVID-19 primarily based totally at the medical manifestations: mild, moderate, intense, and essential disease. Severe, in particular essential, instances are normally complex through different organ dysfunctions, such as septic shock, coronary heart failure, and disseminated intravascular coagulation (DIC).

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

7.Transfusion Medicine

A physician who looks after the maintenance of an adequate blood supply, blood donor and patient-recipient safety is specialized in transfusion medicine. It deals with the issues of clinical transfusion practices, immunohematology, blood donation and other clinical tests for transfusion transmittable diseases, patient blood management, therapeutic apheresis, cellular therapy and coagulation. Blood Transfusion is a medical procedure where donated blood is transfused to a recipient. Blood transfusion helps patients to survive from iron deficiency Anaemia, Sickle cell ailment and haemorrhage. The requirement of blood is progressively growing even though some branches of medicine have brought down its certainty. The transfusion medicine specialists predict good scenarios by the year 2025, at best in the developing countries.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

8. Blood Disorders Diagnosis & Treatment

Blood disorders are of different types and are categorized based on the various components in blood – red blood cells, white blood cells, and platelets. Blood disorder involves blood proteins that are integral in the clotting of blood. Chemotherapy, Radiation is the prescribed treatments for Lymphoma and Leukaemia. Stem cell transplant/chemotherapy can prolong life for patients suffering with multiple myeloma. If there isn’t sufficient platelet or too many platelets then the common platelet disorders obtained are Immune Thrombocytopenia and Thrombasthenia. In certain cases treated with medicines and involves platelet transfusion and severe cases of a bone marrow transplant. Iron deficiency anemia can be treated by intake of iron pills. In some cases injection of a synthetic hormone to stimulate the growth of red blood cells is prescribed for chronic diseases related anemia. For sickle cell anemia, bone marrow transplant or stem cell transplant is the only treatment for the condition.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

9. Pediatric Hematology

Pediatric Hematology is a subdivision of Hematology which handles the blood disorders in children and treats them with care. Due to lack of knowledge and awareness among the children may lead to a delay in diagnosis and treatment of blood disorders. Blood disorders contain problems with red blood cells, white blood cells, platelets, coagulation or bone marrow. The blood disorders in the Paediatric age group are often different from that in adults hence needing specialised care. Haematologists have the experience to manage and treat a child or youngster with hematologic disorders. Infants or Children with blood diseases and blood cancers need special attention than adults.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

10.  Hematology Oncology

Hematology Oncology specialists, specialize in treating, screening and preventing blood malignancy and cancer. Hematology-oncology assimilates such sicknesses as anaemia, haemophilia, sickle cell disease, thalassemia, leukaemia and lymphoma. In clinic they oversee Chemotherapy regimens and work with Radiologists and Radiation Oncologists. Experts provide healthcare to the hospitalized patients by treating their blood ailments such as sickliness, draining scatters, and coagulating issues. Hematologists - Oncologist specialize in treating blood cancers.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

11. Blood Transfusion

Blood transfusion can be life-renewing and is a primary element of many advanced surgeries and clinical interventions. In spite of the fact that blood components are expensive they may periodically have serious deleterious effects and supplies are inadequate. By overlooking inessential and unreasonable transfusions is good for patients and have to ensure blood supplies encounter the increasing demands of an ageing population. Once in a while, ailment can make it difficult for your body to produce good blood. A few conditions that might require transfusion treatment.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

12. Leukaemia and Lymphoma

Leukaemia either it could be acute or chronic. In acute leukaemia, the cancer develops rapidly. Chronic leukaemia is more common and pile up slowly at the beginning stages. There are four main types of leukaemia each categorized by the multiplication and origins of the cancer cells. These include:

1.Acute myeloid leukaemia
2.Chronic myeloid leukaemia
3.Acute lymphocytic leukaemia
4.Chronic lymphocytic leukaemia

Lymphoma pointedly strikes the lymph nodes. Based on the origin of the cancer cells the type of lymphoma is determined. It might begin in the lymphatic system or in the white blood cells and these cancers are also called non-Hodgkin lymphomas. They prevail when T- or B-cells within white blood cells become malignant.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

13. Therapeutic Apheresis

Apheresis is a process of separating the individual components of blood using a machine. Apheresis is commonly done on donors where the entire blood is filtered to obtain individual components i.e., red blood cells, platelets, plasma based on specific gravity to use for transfusion in different patients. Apheresis can also be used as a therapeutic agent to treat various disorders. Therapeutic apheresis is a treatment which removes abnormal cells in the blood which are correlated with a certain disease states. The basic premise of therapeutic apheresis is that removal of certain pathologic cells will reduce organ or tissue damage and may permit reversal of a pathologic process. In order to prevent volume depletion during therapeutic plasmapheresis, the volume of plasma removed must be replaced by plasma, colloid, or crystalloid. Some complications differ depending on whether the replacement fluid is allogeneic (donor) plasma or albumin.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

14. Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation

Multiple myeloma is a cancer that arises from a type of white blood cells called as plasma cell myeloma. Plasma cells become abnormal, proliferate when tumors accumulate in the different parts of the body especially in the bone marrow. Myeloma is diagnosed and monitored by measuring the levels of paraproteins. Amyloidosis is a rare disease that occurs when an abnormal protein called amyloid builds up in your organs and interferes with their normal function. Amyloid is formed from several different types of protein in the body. Treatments for amyloidosis may include medications to reduce amyloid production and to control symptoms and some people may benefit from organ or stem cell transplants.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

15. Patient Blood Management

Blood transfusion comprises of all clinical aspects of blood transmission and promotes safe practice and proper use of blood components. There is a risk and also benefits of transfusion as well as close monitoring of patients. Blood is transmitted to patient when there is evidence for potential benefit. It is vital to follow an evidence-based and multidisciplinary approach for the patient care in need for blood transfusion. Patient Blood Management (PBM) incorporates with patient health condition and clinical management decision-making process. PBM can reduce allogeneic blood transfusions and health-care costs while making sure that blood components are handy for patients. This includes implementation of appropriate indications, depreciation of blood loss and enhancement of patient red cells.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

16.  Immunohematology

Immunohematology is the study of the interactions between the immune system and blood components, focusing on blood typing, cross-matching, and identifying antibodies that can affect blood transfusions. This field is crucial for ensuring the compatibility of donor and recipient blood, thereby preventing adverse reactions. Immunohematologists work to identify and understand blood group antigens and antibodies, which is essential for safe blood transfusions and organ transplants. Advances in immunohematology have improved the accuracy and safety of blood matching processes. The field also plays a vital role in diagnosing and managing autoimmune hemolytic anemias and other blood-related immune disorders.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

17.  Case reports of Hematology

A case report is a description of important medical observations that are unnoticed or unobserved in clinical trials. A case report is a summarization of the signs, symptoms, diagnosis and treatment of an individual patient. Hematology case reports have helpful roles in medical research and evidence-based drugs. Specifically, they need facilitated recognition of rare or unusual clinical condition, unusual side effects to therapy or response to treatment and special use of imaging modalities or diagnostic tests to assist diagnosis of a disease. Case reports might also play a key role in guiding the personalization of treatments in clinical aspects.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

18. Thalassemia

Thalassemia is a genetic blood disorder characterized by the abnormal production of hemoglobin, leading to anemia and other health complications. It results from mutations in the genes responsible for hemoglobin production, causing red blood cells to break down prematurely. Symptoms can range from mild to severe, including fatigue, weakness, and pale skin. Management of thalassemia often involves regular blood transfusions and iron chelation therapy to remove excess iron from the body. Advances in gene therapy and other treatments are being explored to improve the quality of life for those affected by thalassemia.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

19. Thrombosis and Coagulation

Thrombosis and coagulation are critical processes in blood clot formation and regulation. Thrombosis occurs when a blood clot forms in a blood vessel, potentially leading to conditions such as deep vein thrombosis (DVT) or pulmonary embolism. Coagulation involves a complex cascade of events where blood components, including platelets and clotting factors, work together to form a stable clot and prevent excessive bleeding. Disorders in coagulation can lead to either increased risk of clotting or bleeding. Advances in understanding these processes have led to improved treatments and preventive measures for thrombotic disorders.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

20. . Transfusion Transmissible Infections

Transfusion-transmissible infections (TTIs) are infections that can be transmitted through blood transfusions, posing significant risks to recipients. Common TTIs include HIV, hepatitis B and C, syphilis, and malaria. Rigorous screening and testing of donated blood are essential to minimize these risks and ensure the safety of blood supplies. Advances in diagnostic techniques have improved the detection of TTIs, enhancing transfusion safety. Ongoing research and strict adherence to blood safety protocols are crucial in preventing the transmission of infections through transfusions.

Recommended Associations: Australian Hematology Association, American Hematology Association, English Cell Therapy Society, English Cell Therapy Association, Canadian Hematology Association, Canadian Association of Cell Therapy, European Hematology Association, European Federation of Stem Cell Research, FDI World Transfusion Medicine Federation, Indian Cell Therapy Association, Global Association for Hematology, Society for Hematology and Cell Therapy, Japanese Society of Blood Transfusion, Japanese Society of Pediatric Hematology, Japan Thrombosis and Coagulation Association

Benefit of Participation

Advantages of Participating in our Conference

The advantages of the Speaker and abstract pages are created in Google on your profile under your name would get worldwide visibility.

• Our comprehensive online advertising attracts 30000+ users and 50000+ views to our Library of Abstracts, which takes researchers and speakers to our webinar.

• Meet with hundreds of like-minded experts who are pioneers in Thyroid and share ideas.

• All participants in the webinar would have a different reason to participate with eminent speakers and renowned keynote speakers in one-to-one meetings.

• A rare opportunity to listen what the world's experts are learning about from the world's most influential researchers in the area of endocrinology at our Keynote sessions.

• Thyro Summit intensive summit schedule, you will acquire experience and expertise in strategic gift preparation that is worth its weight golf, forming an impressive array of recognised professionals.

• Best Poster Award nominations.

• Award for Outstanding Young Researcher.

• Group Registration Advantages.

Benefits of Participation for Speaker

• Worldwide appreciation of the profile of Researchers.

• Obtain credits for rowth.

• Explore the latest of cutting edge analysis.

• Make long-term bonds at social and networking activities.

• An ability to advertise one page in the distribution of abstract books and flyers that ultimately gets 1 million views and adds great value to your research profile.

• Learn a transition beyond your area of interest to learn more about new subjects and studies away from your  core subject of Endocrinology. We have distinctive networking, learning and enjoyable integration into a single package.

Benefits of Participation for Delegate

• Professional Development-Improve understanding and knowledge.

• Attendance at summit supports, rejuvenates and energises delegates.

• Your involvement in our summit  will help with a new methodology and ideology that can be used to broaden the outcomes of businesses or industries.

• Opportunities for thyroid summit researchers and experts in the same field to meet and exchange new ideas through summit.

Benefit of Participation for Sponsor

• Exposure to the international environment would increase the possibility of new companies.

• Opportunity to demonstrate your company's latest technologies, new products, or service your business to a wide range of  international participants.

• Increase business by our conference participants through lead generation.

• It takes a lot of time, effort and drive to create a successful company, so it's always nice to have a network of colleagues and associates to draw energy from individuals who share a common drive and  objective.

• Summit in endocrinology provide opportunities for more attention and contemplation that could help you move your company to the next stage.

• Benchmarking main organization plans and moving it forward.

• Get feedback from trustworthy people at our conference to your company questions and challenges.

• On our summit banner, website and other proceedings, branding and marketing content, the advertising logo of your company.

Benefit of Association for Collaborators

• Nobody has this massive visitors to endocrinology in the world, this is the best forum to highlight endocrinology .

• Creating long-lasting peer relationships.

• In our summit banner, website and other proceedings, branding and marketing material, promotional content and your Organization logo will increase your number of subscribers/members by 40%.

• The exposure of our event to your Company listing in the Global Business forum will have a great effect on your association.

• Your representatives can network to update their knowledge and understanding of your organisation and services with key summit delegates.

Thyroid advertising materials such as posters, brochures, pamphlets, services that will be circulated to hospitals, universities, society and researchers will be integrated with information. 

Market Analysis

Hematology Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2027. Blood disorders are substantial health and economic burden in worldwide populations. The growing prevalence of common blood disorders such as anemia particularly among women and hemophilia has been driving clinical advances in the hematology market. The prevalence of certain blood cancer in developed countries is also bolstered awareness for hematology testing. The Global Hematology Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
                                                   
                                   

The increasing incidence of blood-related disorders is expected to propel the growth of the global hematology market. The rising incidence of blood cancer is a major factor contributing to the growth of the market. For instance, according to GLOBOCAN 2018, more than 1.85 million new blood cancer cases are expected to be diagnosed in 2040 across the globe. Furthermore, according to the American Cancer Society, Non-Hodgkin lymphoma is one of the more common types of cancer in the U.S., accounting for 4% of all cancer cases. An estimated 74,680 patients were diagnosed with Non-Hodgkin lymphoma in the U.S. in 2018. In addition, increasing incidence of hemophilia and sickle-cell anemia is expected to drive the growth of the global hematology market. For instance, according to the World Federation of Hemophilia’s (WFH) 2018 statistics, around 440,000 people had hemophilia, out of which around 173,000 people were diagnosed with hemophilia A or B in 2017 globally. Furthermore, as per the World Health Organization, in 2018, the prevalence of anemia in children was around 45% and 12% in men, and it is increasing rapidly all over the world. Similarly, According to the National Institute of Health (NIH), anemia affects 30% of women of reproductive age and 40% of pregnant women, globally. Stringent regulatory and reimbursement policies on product launches, as well as product recalls due to safety violations are projected to hamper the growth of the market over the forecast period. For instance, in April 2017, Sysmex, a Japanese medical devices company recalled 3,682 XN Series Automated Hematology Analyzers, owing to increases in incidences of fire caused due to improper alignment of an internal protective sheet that protects electronic components from salty reagents used in hematological sample analysis.



                                      
 

Furthermore, an increasing number of product launches is expected to propel the market growth over the forecast period. New product launches by key players operating in the global market are expected to propel the growth of the global hematology market. For instance, in May 2018, Beckman Coulter, a Danaher Corporation company that develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing, launched the DxH 900 hematology analyzer which performs complete blood count and white blood cell differential tests with minimal repeats for application in mid-to high-volume clinical laboratories. In February 2018, Horiba, a Japanese manufacturer of precision instruments for measurement and analysis, launched the Yumizen G range of semi-automatic to fully automatic hemostasis solutions for clinical testing. Moreover, the increasing adoption of certifications for quality enhancement by key players operating in the global hematology market is expected to propel the market growth over the forecast period. In November 2017, Sysmex received CLIA Waiver certification under the U.S. regulatory approval system for the XW-100 automated hematology analyzer. It is the latest product in the hematology field targeting the U.S. market.

Visa Trip Advisor

Planning a trip to Madrid, Spain? Attend our Meeting!

Issue with VISA?

To support participants in their VISA application process, we provide VISA support documents as follows:

1.Official Letter of Invitation
2.Official Letter of Abstract Acceptance
3. Receipt of Payment

Points to note:    

Visa Letter (official letter of invitation) will be issued only after successful registration and payment for the conference.

1. Visa Letters can be issued only for the individual accepted to attend the conference.
2. Please contact the Program Manager – Joe Howard, via
3. contact@globalconferencemeet.com to arrange for a Visa Letter.

Kindly provide us with the following information for Visa Letters:

1. Your name as it appears on your passport
2. Passport Scan Copy (passport number and date of birth)
3. Abstract Acceptance letter

Payment Methods:

1. Payment Gateway - RAZORPAY
2. Bank-to-Bank transfer

Having trouble with registration?

Please contact Program Manager – Amelia Grace via contact@globalconferencemeet.com. The Hematology 2025 team will provide you with an INVOICE for the requested price, enabling you to make the Bank-to-Bank transfer.

Past Conference Report

HEMATOLOGY 2025

Conference Series is proud to announce the “4th European Congress on Hematology” (HEMATOLOGY 2025), to be held on February 24-25, 2025, in Madrid, Spain. This remarkable event will feature an exceptional array of speakers who will share their expertise and discuss innovative topics related to hematology research. The conference, hosted by Conference Series, is expected to attract young researchers, business delegates, and talented students from over 25 countries, all united under the theme “Innovations in Hematology from Research to Care.” Attendees will engage in insightful discussions on subjects such as anemia, leukemia, lymphoma, coagulation disorders, and other related areas. The exchange of conceptual and practical knowledge aims to foster organizational collaborations and accelerate scientific progress.

The Organizing Committee extends its gratitude to moderator Andreas Lim from the Federal Research Centre of Hematology-RAS, Russia, for his contributions to the smooth functioning of the conference. The event will commence with an opening ceremony, followed by a series of lectures from Honourable Guests and keynote speakers. Notably, Pawan Singhal is expected to deliver highly informative presentations that will greatly enhance the conference's prestige. The success of the 4th European Congress on Hematology will be made possible by the support of an international, multi-professional steering committee and the coordination of the Journal of Hematology & Oncology and the Journal of Blood Disorders & Therapy.

Following the success of HEMATOLOGY 2025, we are excited to announce the “5th European Congress on Hematology,” scheduled for February 2026 in Madrid, Spain, with the theme "Advancing Hematologic Care and Research."